Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.75
Ask: 7.25
Change: 0.00 (0.00%)
Spread: 0.50 (7.407%)
Open: 7.00
High: 7.00
Low: 7.00
Prev. Close: 7.00
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Exec

5 Jun 2006 07:00

Phytopharm PLC05 June 2006 Company Contact: U.K. Investor Relations Contact:Phytopharm plc Financial DynamicsDr Richard Dixey David Yates / Ben Atwell +44 207 831 3113+44 7867 782000Dr Daryl Rees+44 1480 437 697www.phytopharm.com Appointment of Non Executive Director GODMANCHESTER, Cambridgeshire, U.K. (June 5 2006) - Phytopharm plc (LSE: PYM;NASDAQBB: PHYOF; PHYOY) ("Phytopharm") announces the appointment with immediateeffect of Mr A D (Sandy) Morrison, former CEO of Lipton Ltd (a Unileversubsidiary) as a Non-executive Board Director of Phytopharm. Mr Morrison (aged 59) has a BSc (Hons) in applied chemistry (Strathclyde) andhas over 20 years experience in general and international management, globalsupply chain and R&D. He was Chief Executive Officer of Lipton Ltd, the globaltea sourcing organization for Unilever with operations in six countries for fiveyears from 2000 to 2006. During Mr Morrison's period as CEO, substantialoperational & financial improvements were made to the Unilever global tea supplychain and he also played a significant part in addressing issues in theinternational tea trade. In the immediate years prior to 2000, Mr Morrison hadsenior international food & beverage roles for Unilever outside the UK, in thesupply chain and in R&D, both at the Rotterdam head office and in the Unileverfood and beverage subsidiary in Australia. Commenting on the appointment, Mr Gordon Stevens, Chairman of Phytopharm, said;"the appointment of a person of this calibre and experience to the Board ofPhytopharm will provide an important asset to the Company and I am delightedthat Sandy will be joining us. This appointment begins a process ofrestructuring of the Board and I look forward to the announcement of furtherappointments in due course." There are no further details required to be disclosed under paragraph 9.6.13R ofthe Listing Rules or Disclosure Rule 3.1.2R. -ENDS- NOTES TO EDITORS Phytopharm plc Phytopharm is a pharmaceutical company with a plant extract division. Thepharmaceutical division is dedicated to the discovery and development of singlechemicals as prescription medicines and the plant extract division is focussedon the development of plant extracts as functional foods and veterinaryproducts.. More information concerning Phytopharm's activities can be found on its web site at http://www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results
3rd May 20187:00 amRNSPlacing to raise ?5.5 million
4th Apr 20187:00 amRNSAgreement
30th Jan 20187:00 amRNSNew contract in progressive supranuclear palsy
22nd Jan 20183:16 pmRNSResult of AGM
22nd Jan 20187:00 amRNSAGM Statement and Board Changes
11th Dec 20177:00 amRNSFinal Results
28th Nov 20177:00 amRNSStrategic and Operational Update
16th Nov 20177:00 amRNSContract to Deploy Biosensors in Clinical Trial
19th Oct 201710:14 amRNSTrading Statement
4th Oct 20177:00 amRNSNew contract to support Phase II clinical trial
28th Sep 20177:00 amRNSNew contract in Huntington's disease
25th Sep 20177:00 amRNSNew Contract with Biopharmaceutical Company
5th Sep 20177:00 amRNSExtension of a 5 year contract
8th Aug 20174:23 pmRNSDirector/PDMR Shareholding
24th Jul 20177:00 amRNSExpansion of Collaboration with Biogen
18th Jul 20177:00 amRNSIXICO hosts Alzheimer Expert Symposium
5th Jul 20177:00 amRNSNew contract for imaging clinical trial services
22nd May 20177:00 amRNSHalf Yearly Report to 31 March 2017
16th May 20179:57 amRNSNotice of H1 Results
12th Apr 201712:41 pmRNSExercise of share options
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSDirector/PDMR Shareholding
29th Mar 20173:30 pmRNSExercise of Share Options
13th Mar 20177:00 amRNSIXICO signs US$1.5m contract
10th Mar 201710:00 amRNSTo present novel sleep measurement technology
9th Feb 20177:00 amRNSGrant of Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.